Illumina NextSeq 2000 System

• Product Service Code: 6640- Laboratory Equipment and Supplies

• NAICS Code: 334516 - Analytical Laboratory Instrument Manufacturing

• Place of Performance: Bethesda, MD 20892

POTS:  24-011179

Description:
This is a notice of intent, not a request for a quotation. A solicitation document will not be issued, and quotations will not be requested.

The National Institutes of Health, Office of Purchasing and Contracts on behalf of the Department of Transfusion Medicine, Center for Cellular Engineering intends to award a firm-fixed priced contract to Illumina Inc. to supply an Illumina NextSeq 2000 System with trade-in of Illumina NextSeq 550.

The Department of Transfusion Medicine (DTM), Center for Cellular Engineering requires to trade in from the existing Illumina NextSeq 550 to upgrade to the Illumina NextSeq 2000 System.  The Department of Transfusion Medicine (DTM), Center for Cellular Engineering manufactures cell and gene therapies for phase I and II clinical trial.  Recently the Food, Drug and Administration published guidance, recommending Potency Assurance for Cellular and Gene Therapy Products.  The goal of a potency assurance strategy is to ensure that every lot of a product released will have the specific ability or capacity to achieve the intended therapeutic effect.   Single-cell sequencing of RNA, DNA-Seq and CITE seq is state of the art techniques in the world, the development and adapting of single-cell lot release assay clinical CAR-T products is crucial for the Potency Assurance.  The new Illumina NextSeq 2000 System will complement the laboratory’s equipment.  The Illumina NextSeq 2000 System is the only instrument compatible with the existing Illumina laboratory equipment and Illumina reagents. 

This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available.  Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.

Interested Parties:
Interested parties capable of providing the same or similar products or services described in this notice may submit a capability statement outlining their capability to perform the described work.  Capability Statements must be received within the time set forth in this synopsis to be considered by the Government. The determination to compete this proposed contract based on responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.

Comments:
Comments to this announcement, referencing this posting number, may be submitted to the CC, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, electronically to the attention of Sheri Eiri, Contract Specialist, sheri.eiri.nih.gov by the due date August 1, 2024 and time marked in this notice.